PCBL Chemical Limited — Investor Meet, 17-01-2025: Analysts/Institutional Investor Meet/Con. Call Updates

1. Financial Performance: PCBL Chemical Limited reported consolidated revenue from operations of INR 2,010 Cr, a 21% increase year-over-year, driven by a 5% increase in sales volume to 144,000 tons in Carbon Black. EBITDA rose by 15% to INR 328 Cr, while PAT improved to INR 93 Cr. The EBITDA per ton in the Carbon Black segment stood at INR 19,868 per ton. For 9M FY25, revenue surged 40% to INR 6,317 Cr, with a 15% YoY growth in sales volume.

2. Future Outlook and Growth Drivers: Management foresees robust growth prospects supported by ongoing capacity expansions, particularly a greenfield project in Andhra Pradesh for a new Carbon Black plant, with initial capacity of 150,000 MTPA expected in two to two-and-a-half years. They aim to enhance operational efficiencies and have launched ECOZENTM6000, a sustainable product.

3. Order Book and Operational Updates: The brownfield expansion in Tamil Nadu completed 30,000 tons, with future phases underway. The expansion of Aquapharm Chemicals is on track for completion by March 2025. Operational challenges such as destocking in Europe and raw material price volatility remain a focus.

4. Analyst Q&A Insights: Analysts probed about declines in Carbon Black spreads, attributed to a combination of crude price impacts and changing product mix. Concerns on Aquapharm’s sequential volume decline were acknowledged, but the management expressed confidence in operational improvements and market positioning strategies to enhance future performance.

5. Market or Regulatory Updates: The management mentioned challenges like competition from Russian imports affecting local margins, but indicated optimism due to strong demand in the tyre industry and restrictions on Russian suppliers in Europe.

6. Strategic Focus Areas: There’s a clear strategic inclination towards expanding market share through new product launches, customer acquisition, and enhancing sustainability initiatives, positioning the company well within the evolving market dynamics.

7. Investor Insight: Observing healthy performance metrics and strategic expansion plans, there’s potential for a ‘buy’ position, especially considering the company’s proactive approach to market opportunities despite headwinds. Management's confidence in recovery trends for both Aquapharm and carbon black segments supports this outlook.